Oral weight-loss drug update exploring trial announcements, industry implications, and what investors and developers should watch next.
Key Takeaways
- Two Hengrui-conducted Phase 3 trials reported positive topline results for the oral GLP‑1
- 120 mg and 180 mg arms achieved mean weight losses of 9.5% and 11%
- Both trials improved blood pressure and lipids and reported no liver safety signal